Financial Performance - Total operating income for the year ended December 31, 2025, was HKD 13,030,000, a decrease of 44.8% from HKD 23,652,000 in 2024[2] - The net loss before tax for 2025 was HKD 6,892,000, significantly improved from a loss of HKD 21,598,000 in 2024, representing a reduction of 68.1%[3] - Basic and diluted loss per share for 2025 was HKD 3.56, compared to HKD 13.73 in 2024, indicating a 74.0% improvement[3] - The company reported a total comprehensive loss of HKD 6,892,000 for 2025, compared to HKD 21,598,000 in 2024, reflecting a 68.1% improvement[3] - The group incurred an operating loss of approximately HKD 6,900,000 in 2025, compared to a loss of HKD 21,600,000 in 2024, indicating a significant improvement[32] Assets and Equity - Total assets decreased to HKD 29,822,000 in 2025 from HKD 33,098,000 in 2024, a decline of 10.0%[4] - Total equity attributable to owners decreased to HKD 28,611,000 in 2025 from HKD 31,862,000 in 2024, a decrease of 10.5%[4] - Cash and cash equivalents dropped to HKD 962,000 in 2025 from HKD 4,268,000 in 2024, a decline of 77.5%[4] - The net asset value as of December 31, 2025, was approximately HKD 28,600,000, a decrease of about HKD 3,300,000 from HKD 31,862,000 in 2024[32] - Non-current assets decreased to HKD 18,133,000 in 2025 from HKD 16,108,000 in 2024, an increase of 12.6%[4] Income and Expenses - The total other income for 2025 was HKD 3,000, compared to HKD 213,000 in 2024, reflecting a significant decline[18] - Administrative expenses increased from approximately HKD 10.6 million to about HKD 11.4 million, primarily due to higher employee benefits expenses[41] Shareholder Actions - The company did not declare or recommend any dividends for the year ended December 31, 2025, consistent with 2024[31] - The company entered into a placement agreement to issue up to 33,936,000 new ordinary shares at a placement price of HKD 0.112 per share, aimed at strengthening the financial position and broadening the shareholder base[48] - The net proceeds from the placement are approximately HKD 3,610,000, with a net placement price of about HKD 0.106 per share[49] - Approximately 55.4% (or about HKD 2,000,000) of the net proceeds will be used for potential investments, while 44.6% (or about HKD 1,610,000) will be allocated for general working capital[49] - The anticipated net proceeds from the rights issue are approximately HKD 49,240,000, assuming full subscription and no change in the number of shares issued[54] - The company plans to allocate about 70% (or approximately HKD 34,470,000) of the net proceeds from the rights issue to investments in listed and unlisted securities, including sectors like AI and renewable energy[54] Market and Economic Context - The S&P 500, Dow Jones, and Nasdaq indices increased by approximately 16.4%, 13%, and 20.4% respectively, benefiting from a successful "soft landing" of the economy and a decisive shift to a loose monetary policy by the Federal Reserve, which reduced interest rates by 75 to 100 basis points[34] - The Hang Seng Index and Hang Seng Tech Index rose by 27.8% and 23.5% respectively, marking the largest annual increase since 2017, driven by the robust development of global artificial intelligence and improved investor sentiment from US-China trade agreements[35] - The trading volume in the Hong Kong stock market doubled in 2025, supported by policy backing and international capital inflow, although total proceeds from investment sales decreased to approximately HKD 12.7 million from HKD 23.4 million in 2024[36] - The outlook for global stock markets remains cautiously optimistic, with expectations of continued recovery driven by strong corporate earnings, particularly in the AI and technology sectors, despite potential risks from geopolitical tensions and inflation pressures[43] Governance and Compliance - The company has adhered to the corporate governance code and has established a governance framework to ensure accountability, fairness, honesty, and transparency[64] - The audit committee consists of three independent non-executive directors, with Mr. Tam as the chairman, and has reviewed the annual performance for the year ending December 31, 2025[66] - The remuneration committee is also composed of three independent non-executive directors, with Mr. Tam serving as the chairman[67] - The nomination committee includes one executive director and three independent non-executive directors, with Dr. Ng as the chairman[68] - The company confirmed that all directors complied with the standard code for securities trading during the year ending December 31, 2025[69] Employment and Workforce - As of December 31, 2025, the company has 15 employees and directors, with compensation aligned with current market practices[63] Other Information - The company has not engaged in any significant acquisitions or disposals of subsidiaries during the year[55] - There were no purchases, sales, or redemptions of the company's shares during the year ending December 31, 2025[70] - The annual results announcement and annual report for the year ending December 31, 2025, will be published on the Hong Kong Stock Exchange and the company's website[74] - The company will hold its annual general meeting on June 12, 2026, with a record date for shareholder voting set for June 12, 2026[72][73] - The company expresses gratitude to all directors, management, and employees for their support and contributions[75] - The chairman of the board is Dr. Lam, and the executive director is Mr. Lee[76][77]

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告 的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 China Castson 81 Finance Company Limited 中國鑄晨 81 金融有限公司 (於百慕達存續之有限公司) (股票代號: 810) 董事會會議通告 中國鑄晨81金融有限公司（「本公司」）董事會（「董事會」）謹此宣佈, 本公司 將於二零二六年三月二十七日(星期五)舉行董事會會議，藉以(其中包括) 批准 本公司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績及其刊 發及其他事項(如有)。 承董事會命 中國鑄晨81金融有限公司 公司秘書 鄭淑芬 香港，二零二六年三月十七日 於本公佈日期，本公司執行董事為李國樑先生；本公司之非執行董事為林文燦 博士及本公司之獨立非執行董事為吳志揚博士、譚旭生先生及羅素芬女士。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Castson 81 Finance Company Limited 中國鑄晨 81 金融有限公司 (於百慕達存續之有限公司） 於本公佈日期，執行董事為李國樑先生；非執行董事為林文燦博士及獨立非執 行董 事為吳志揚博士、譚旭生先生及羅素芬女士。 香港，二零二六年三月十三日 資產淨值 於二零二六年二月二十八日，以已發行 203,643,187 股普通股計算，本公司每股未經 審核綜合資產淨值約為 0.18港元。 （股份代號：810） ...

CHINA CASTSON 81 FINANCE COMPANY LIMITED 中 國 鑄 晨 81 金 融 有 限 公 司 (Continued into Bermuda with limited liability) （於百慕達存續的有限公司） （Stock Code 股份代號：810） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders. 13 March 2026 China Castson 81 Finance Company Limited (the "Company") – NOTICE OF PUBLICATION OF PROSPECTUS (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.irasia.com/listco/hk/810 an ...

CHINA CASTSON 81 FINANCE COMPANY LIMITED China Castson 81 Finance Company Limited (the "Company") – NOTICE OF PUBLICATION OF PROSPECTUS (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.irasia.com/listco/hk/810 and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to acce ...

To be valid, the whole of this Provisional Allotment Letter must be returned. 本暫定配額通知書必須整份交還，方為有效。 IMPORTANT 重要提示 Reference is made to the prospectus issued by China Castson 81 Finance Company Limited (the "Company") dated 13 March 2026 in relation to the Rights Issue (the "Prospectus"). Capitalised terms used herein shall have the same meanings as those defined in the Prospectus unless the context requires otherwise. 茲提述中國鑄晨81金融有限公司（「本公司」）就供股所刊發日期為二零二六年三月十三日之供股章程（「供股章程」）。除文義另有所指外，本暫定配額通知 書所用詞彙與供股章程所界定者具有相同 ...

此乃要件 請即處理 閣下如對本供股章程任何方面或應採取之行動有任何疑問，應諮詢持牌證券交易商或註冊證券機構、銀行經理、律師、專業會計師或其他 專業顧問。 閣下如已售出或轉讓名下所有中國鑄晨81金融有限公司的股份，應立即將供股章程文件送交買主或承讓人，或經手買賣或轉讓之銀行、或 持牌證券交易商或註冊證券機構或其他代理商，以便轉交買主或承讓人。然而，供股章程文件不應派發、轉發或傳送至任何作出有關行為 即構成違反當地相關證券法例或法規的任何司法權區。 香港交易及結算所有限公司、聯交所及香港結算對供股章程文件之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概 不就因供股章程全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 各份供股章程文件之副本連同本供股章程附錄四「18.送呈公司註冊處處長之文件」一段內所指明的文件，已根據公司（清盤及雜項條文）條例 第342C條的規定送呈香港公司註冊處處長登記。香港公司註冊處處長、聯交所及香港證券及證監會對上述任何文件的內容概不負責。 閣下應細閱供股章程文件全文，包括本供股章程「董事會函件」中「買賣股份及供股股份的風險警告」一段所載對若干風險及其他 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國鑄晨81金融有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00810 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.01 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.01 | HKD | | 200,000,000 | 本月底法 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公佈僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約。 China Castson 81 Finance Company Limited 中國鑄晨8 1金融有限公司 1 股東特別大會由獨立非執行董事譚旭生先生擔任主席。全體董事已親身或以電子 方式出席股東特別大會。 股東特別大會的投票表決結果 股東特別大會之投票表決由本公司之香港股份過戶登記分處卓佳證券登記有限公 司負責監票。所有決議案均獲獨立股東通過，投票表決結果如下： | 普通決議案 （附註） | 票數(%) | | | --- | --- | --- | | | 贊成 | 反對 | | 批准供股、包銷協議及其項下擬進行之交易 | 27,690,042 | 0 | | | 100.00% | 0.00% | | 特別決議案 （附註） | 票數(%) | | | | 贊成 | 反對 | | 批准清洗豁免及其項下擬進行之交易 | 27,690,0 ...

1 1. 本公司確認，於最後實際可行日期，除不可撤銷承諾及包銷協議外，本公司 任何附屬公司、本公司或本集團任何成員公司的退休金基金，或根據收購守 則中「一致行動人士」定義第(5)類而推定與本公司一致行動的人士，或根據 收購守則「聯繫人」定義第(2)類之本公司聯繫人（但豁免主要交易商及豁免基 金經理除外）的人士，於有關期間內並無擁有或控制本公司任何股份或任何 證券、可轉換證券、認股權證、期權或衍生工具。 2. Goodchamp（作為包銷商）乃本公司主要股東，於最後實際可行日期持有本公 司已發行股本總額約17.34%權益。於供股完成後，Goodchamp、林博士及與 彼等任何一方一致行動人士擬繼續經營本集團現有業務，且無意(i)對本集團 業務作出任何重大變動，包括重組本集團固定資產（本集團金融資產除外）； (ii)縮減、終止或出售本集團任何現有業務、營運及資產（本集團金融資產除 外）；或(iii)終止本集團僱員的持續僱用關係。 董事會同時謹此澄清，Goodchamp已根據收購守則規則26豁免事項之附註1，向執 行人員申請清洗豁免。執行人員已同意授予清洗豁免，惟須待獨立股東親身或透 過受委代表於股東特別大會上以投 ...